Global Idiopathic Hypersomnia Treatment Market - Restraint
Side effects of current off-label drugs for hypersomnia which include aggressive behavior & dependence and no approved product are some of the major factors that are expected to hinder growth of the global idiopathic hypersomnia treatment market. Moreover, declining less patient pool for clinical trials is also a major setback for the global idiopathic hypersomnia treatment market, which is expected to hamper growth of the market.
Increase in lifestyle diseases such as anxiety, depression, and increasing diagnosis rate of hypersomnia are expected to drive the market growth over the forecast period
Growing incidence of lifestyle diseases such as anxiety, depression, etc. caused by behavioral changes, social activities, which affects the sleep cycle is the major factor responsible for growth of the global idiopathic hypersomnia treatment market. These changes lead to anxiety, depression, & other health issues, in which patients feel tired during the daytime and are more prone to hypersomnia. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the U.S. of age 18 and older, or 18.1% of the population every year.
Furthermore, increasing diagnosis rate of hypersomnia coupled with technological advancements for diagnosis of hypersomnia are expected to fuel growth of the global idiopathic hypersomnia treatment market. For instance, multiple sleep latency test (MSLT) is the standard tool used to diagnose narcolepsy and idiopathic hypersomnia, which is offered at AASM-accredited sleep centers in the U.S.
Increasing number of pipeline products is expected to drive the market growth over the forecast period
Rising number of pipeline products for idiopathic hypersomnia treatment is also a major factor that is expected to boost growth of the global idiopathic hypersomnia treatment market. For instance, in January 2020, Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company Limited initiated the phase1 study of a single intravenous infusion dose of TAK-925 in participants with idiopathic hypersomnia.
Idiopathic Hypersomnia Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients